Acquisition of Selective IgA Deficiency in Juvenile Idiopathic Arthritis after Immunosuppressive TreatmentBoris Hugle, Fabian Speth, Klaus Warnatz, Michael Schlesier, Manuela Krumrey-Langkammerer, Volker Schuster, Haas Johannes-Peter.
Selective IgA deficiency is the most frequent primary immunodeficiency and is associated with an increased rate of respiratory infections in susceptible patients. Juvenile idiopathic arthritis is an autoimmune disease in children affecting the joints and is frequently treated with mild to moderately active immunosuppressive medications. We describe a pediatric patient with juvenile idiopathic arthritis who developed a selective IgA deficiency at age 4 years, with well documented prior IgA levels within normal range for age. This girl was previously diagnosed with arthritis at age 2 years and was treated with methotrexate starting at age 24 months, and etanercept for 18 months starting at age 32 months. Development of IgA deficiency occurred after discontinuation of etanercept treatment. She did not exhibit an increased rate of infections or other clinical signs of immunodeficiency. A work-up for immunodeficiency demonstrated increased levels of transitional B-cells, but no other abnormal findings.
Congenital IgA deficiency is well known to be linked to autoimmune diseases. Acquired IgA deficiency has previously been described in a very small number of pediatric and adult patients, usually associated with some form of immune dysregulation or inciting event. Four patients with juvenile arthritis with acquired IgA deficiency of varying levels have been reported, but biologic agents have not been implicated previously.
Iga deficiency, juvenile idiopathic arthritis, acquired immunodeficiency
Journal of Complementary Medicine Research
SUBMIT YOUR ARTICLE NOW